Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Revenue - Disaggregation of Revenue (Details)

v3.24.1.1.u2
Note 3 - Revenue - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Total revenue $ 53 $ 1,936
Pfizer [Member]    
Total revenue 6 1,423
Astra Zeneca A B [Member]    
Total revenue 0 434
Les Laboratoires Servier And Institut De Recherches Internationales Servier [Member]    
Total revenue 47 (74)
Genentech [Member]    
Total revenue $ 0 $ 153